Phase IV Trial to Compare the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) With One- or Two-dose Regimen and Live Attenuated HAV With One-dose Regimen in Chinese Young Adults, and to Evaluate the Immunogenicity of a Booster Dose
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Hepatitis A vaccine (Healive) (Primary) ; Hepatitis A vaccine live
- Indications Hepatitis A
- Focus Therapeutic Use
- Sponsors Sinovac Biotech
- 05 Jun 2013 New trial record